Similarly, Maxim selling at this level, equates to a we-name-the-price-IPO-for-our-preferred-clients. In the short run, the lower the stock price the better, as far as the firm is concerned.
Once a few million (or more) shares are bought on the cheap the PR machine will soon arrive.
While I'm not making any lofty predictions in terms of price targets, you better believe that Maxim isn't in the business of losing money. The stock will head north, once their position is sizable and/or the money has been generated for clinical trials and operations.
For the uninitiated, Dr. Mullan hasn't been paid a salary in a couple of years. But he has accumulated a heap of shares. His payday comes when the stock takes off. He truly deserves it, too! He obviously believes in this molecule and has put in the work to (eventually) get an IND.
Do your own due diligence. Not to be construed as financial advice. Good luck!
